Evidence map›Paper›PMID 29781049›Full record

ArticleEuropean journal of clinical pharmacology2018

Effects of vitamin K epoxide reductase complex 1 gene polymorphisms on warfarin control in Japanese patients with left ventricular assist devices (LVAD).

Kazuki Nakagita, Kyoichi Wada, Yutaro Mukai, Takaya Uno, Ryoji Nishino, Sachi Matsuda, Hiromi Takenaka, Nobue Terakawa, Akira Oita, Mitsutaka Takada

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Kazuki NakagitaDepartment of Pharmacy, National Cerebral and Cardiovascular Center, Suita, Japan.
Kyoichi WadaDepartment of Pharmacy, National Cerebral and Cardiovascular Center, Suita, Japan.
Yutaro MukaiDepartment of Pharmacy, National Cerebral and Cardiovascular Center, Suita, Japan.
Takaya UnoDepartment of Pharmacy, National Cerebral and Cardiovascular Center, Suita, Japan.
Ryoji NishinoDepartment of Pharmacy, National Cerebral and Cardiovascular Center, Suita, Japan.
Sachi MatsudaDepartment of Pharmacy, National Cerebral and Cardiovascular Center, Suita, Japan.
Hiromi TakenakaDepartment of Pharmacy, National Cerebral and Cardiovascular Center, Suita, Japan.
Nobue TerakawaDepartment of Pharmacy, National Cerebral and Cardiovascular Center, Suita, Japan.
Akira OitaDepartment of Pharmacy, National Cerebral and Cardiovascular Center, Suita, Japan.
Mitsutaka TakadaDivision of Clinical Drug Informatics, Kindai University School of Pharmacy, 577-8502, 3-4-1, Kowakae, Higashi-osaka, Osaka, 577-8502, Japan. takada@phar.kindai.ac.jp.
National Cerebral and Cardiovascular Center · JPKindai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to investigate relationships between times in therapeutic range (TTR) or warfarin sensitivity indexes (WSI) and VKORC1-1639G>A and CYP2C9 polymorphisms in patients with left ventricular assist devices (LVAD).

methodsSevere heart failure patients who received LVAD from January 1, 2013 to October 31, 2017 were recruited. Relationships between TTR or WSI and VKORC1-1639G>A and CYP2C9 gene polymorphisms were investigated immediately after LVAD implantation (period 1) and immediately prior to hospital discharge (period 2).

resultsAmong 54 patients, 31 (72.1%) had VKORC1-1639AA and CYP2C9*1/*1 (AA group) polymorphisms and 12 (27.9%) had VKORC1-1639GA and CYP2C9*1/*1 (GA group) polymorphisms. During period 1, mean prothrombin time-international normalized ratio (PT-INR) values were significantly higher in the AA group than in the GA group (2.21 vs. 2.05, p < 0.0001). Mean WSI values were 1.68-fold greater in the AA group than in the GA group (1.14 vs. 0.68, p < 0.0001). In addition, times below the therapeutic range (TBTR) in the GA group were significantly greater than in the AA group during period 1 (39.8 vs. 28.3%, p = 0.032), and insufficient PT-INR was more frequent in the GA group than in the AA group. However, mean PT-INR values during period 2 did not differ and no significant differences in TTR, TATR, and TBTR values were identified. In subsequent multivariable logistic regression analyses, the VKORC1-1639GA allele was significantly associated with insufficient anticoagulation.

conclusionPatients with the VKORC1-1639GA and CYP2C9*1/*1 alleles may receive insufficient anticoagulation therapy during the early stages after implantation of LVAD, and VKORC1-1639G>A and CYP2C9 genotyping may contribute to more appropriate anticoagulant therapy after implantation of LVAD.

Indexed as

Heart-Assist DevicesAdultAnticoagulantsAsian PeopleCytochrome P-450 CYP2C9FemaleGenotypeHeart FailureHeart VentriclesHumansJapanMaleMiddle AgedPolymorphism, GeneticTreatment OutcomeVitamin K Epoxide ReductasesAnticoagulantsCYP2C9 protein, humanCytochrome P-450 CYP2C9Vitamin K Epoxide ReductasesVKORC1 protein, humanWarfarinCYP2C9Left ventricular assist deviceTime in therapeutic rangeVKORC1-1639G>AWarfarinWarfarin sensitivity index

Identifiers

PMID29781049
OpenAlexW2803273395

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.